Trial Profile

An Open-label Phase 1/2 Study to Evaluate the Safety, Biological Response and Efficacy of a Single Dose of Temferon (autologous CD34+-enriched Hematopoietic Stem and Progenitors Cells Genetically Modified with Human Interferon-α2) in Patients with Metastatic Renal Cell Carcinoma

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 15 Jun 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Interferon alpha 2 gen e therapy-GenentaScience (Primary) ; Busulfan; Cabozantinib; Filgrastim; Lenograstim; Pembrolizumab; Plerixafor
Indications Renal cell carcinoma
Focus Adverse reactions; Therapeutic Use
Sponsors Genenta Science

19 Mar 2025 According to Genenta Science media release, company announced 20 Million EUROs financing to support funding this phase 1/2a trial.
09 Jan 2025 According to a Genenta Science media release, company expects to treat six patients by the end of the first half of 2025.
12 Dec 2024 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com